Prof. Péter Ferdinandy is listed in the global Highly Cited Researcher 2014, 2017, 2020, and 2021 databases acknowledging the world’s most influential scientists. He counts more than 300 papers and 5 patent families. His work is cited more than 18000 times and his Hirsh index is 69.

He received an MD diploma in 1991 and a Ph.D. in 1995 at the University of Szeged, Hungary. He became a registered clinical pharmacologist in 1999. He founded the cardiovascular research group at the Biochemistry Department, University of Szeged, Hungary. He did his postdoctoral training for 2 years at the Department of Pharmacology, University of Alberta, Edmonton, Canada, as a fellow of the Medical Research Council of Canada.

After his postdoctoral training, he returned to Hungary and accomplished an MBA training received an MBA diploma in finance and quality management in 2004 from the Budapest University of Technology and Economics.

He founded Pharmahungary Group, a group of R&D companies ( that have been involved in more than 250 drug/medical device development projects since their foundation in the early 2000s.

He also continued his academic carrier and became the director of the Department of Pharmacology and Pharmacotherapy and the head of the Cardiometabolic Research Group at Semmelweis University, Budapest ( in 2011, and became vice-rector for science and innovations of the Semmelweis University in 2018.

Péter Ferdinandy was the president of the International Society for Heart Research, European Section, and the chair of the Working Group of Cellular Biology of the Heart of the ESC. Currently, he is the president of the Hungarian Society of Experimental and Clinical Pharmacology (


Network Medicine and Drug Repurposing in Cardiovascular DiseaseWebinars on-demand(ReviewTreatmentHypolipidemic drugs)